Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders.
Central nervous system neuroinflammatory disorders in Asian/Pacific regions.
Differential transcriptional response profiles in human myeloid cell populations.
Voiding Dysfunction in Multiple Sclerosis.
Fumaric acid esters promote neuronal survival upon ischemic stress through activation of the Nrf2 but not HIF-1 signaling pathway.
New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients
Hypovitaminosis D upscales B-cell immunoreactivity in multiple sclerosis.
The role of pre-morbid intelligence and cognitive reserve in predicting cognitive efficiency in a sample of Italian elderly.
Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica.
Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies.
Pushing Forward: Remyelination as the New Frontier in CNS Diseases.
Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis.
Effects of dimethyl fumarate on lymphocyte subsets.
Avonex drug warning letter, severe hypatic injury
UCSF Seminar: "Imaging spinal cord gray matter atrophy in MS using SF-SIGMA. Is neuronal loss a key mediator of MS disability?"
Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis.
Dimethyl fumarate induces necroptosis in colon cancer cells through glutathione depletion/ROS increase/MAPKs activation pathway.
Clinical Reasoning: Left hemiparesis, ataxia, and optic neuritis in a child previously treated for pineoblastoma.
Decreased systemic IL-7 and soluble IL-7Rα in multiple sclerosis patients.
European Medicines Agency accepts Marketing Authorization Application for conditional approval of masitinib in the treatment of pancreatic cancer
CombiRx for MS not better than monotherapy
The nature of genetic susceptibility to multiple sclerosis: constraining the possibilities.
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.
Standing up in multiple sclerosis (SUMS): protocol for a multi-centre randomised controlled trial evaluating the clinical and cost effectiveness of a home-based self-management standing frame programme in people with progressive multiple sclerosis.

Pages